Work

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy

Year: 2017

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.70.6267

Authors: Ander Urruticoechea, Mohammed Rizwanullah, Seock-Ah Im, Antonio Carlos Sánchez Ruiz, István Láng, Gianluca Tomasello, Hannah Douthwaite, Tanja Badovinac Crnjevic, Sarah Heeson, Jennifer Eng-Wong, Montserrat Muñoz

Institutions: Beatson West of Scotland Cancer Centre, Hospital Universitario Puerta de Hierro Majadahonda, Institut Català d'Oncologia, Onkologikoa, GEICAM – Spanish Breast Cancer Group

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Army Research Office

OpenAlex ID: W2609953159

FWCI: 5.496

Cites: 24

Cited by: 121

Related to: 10